Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Hexaell Biotech logo — Pioneering the future of stem cell and artificial organ tech...

Hexaell Biotech

Pioneering the future of stem cell and artificial organ technology with breakthrough solutions for liver failure treatment.

Founded 2015 Series A Total: $7.27M Biotechnology, Health Care

General Information

Company Name Hexaell Biotech
Founded Year 2015
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Hexaell Biotech. To contact Hexaell Biotech, visit hexaell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Hexaell Biotech compare?

A PDF of Hexaell Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Hexaell Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Hexaell Biotech

Hexaell Biotech is a groundbreaking startup focused on advancing stem cell and artificial organ technology, with a particular emphasis on innovative solutions for liver failure treatment. Leveraging pioneering research from the Chinese Academy of Sciences, which has been prominently featured in prestigious publications like Nature and Cell Stem Cell, the company has established itself as a trailblazer in the field. With the rights to iHep and HiHep technologies, Hexaell Biotechnology has developed bio-artificial liver medical devices designed to emulate liver function and address liver failure diseases. The company's efforts have culminated in the successful completion of pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. Founded in 2015, Hexaell Biotechnology operates within the Biotechnology and Health Care industries, aiming to drive meaningful advancements in medical technology. Its most recent milestone is a $7.27M Series A investment secured on 25 December 2018, with funding coming from prominent investors including Hyfinity Investments, Sherpa Healthcare Partners, and Breakthrough Capital. This injection of capital is poised to further propel the development and deployment of the company's pioneering solutions, solidifying its position at the forefront of innovation in the medical technology landscape.

Business keywords: Stem Cell Research, Artificial Organ Technology, Liver Failure Treatment, Biotechnology Start-up, Chinese Academy of Sciences, Pilot Clinical Studies, Bio-Artificial Liver, Disruptive Technologies, Nature Publication, Cell Stem Cell Publication, iHep Technology, HiHep Technology, Liver Function Replication, Hepatopathy Centers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $7.27M 3
Hyfinity Investments
Hyfinity Investments, Sherpa Healthcare Partners +1
25 Dec 2018

Hexaell Biotech Alternatives & Competitors

View All Alternatives
Hexaell Biotech vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care
Hexaell Biotech vs
苏州吉美瑞生医学科技有限公司
苏州吉美瑞生医学科技有限公司

Pioneering the future of regenerative medicine with the world’s first autologous stem cell treatment...

Series B
5 employees
Biotechnology, Health Care
Hexaell Biotech vs
Blue Cell Therapeutics
Blue Cell Therapeutics Denmark

We are dedicated to develop novel stem cell therapies to treat chronic diseases

Venture round
15 employees
Biotechnology, Health Care
View all alternatives

FAQ About Hexaell Biotech

Pioneering the future of stem cell and artificial organ technology with breakthrough solutions for liver failure treatment.
Hexaell Biotech was founded in 2015.
Hexaell Biotech operates in Biotechnology and Health Care. Its work centres on Stem Cell Research, Artificial Organ Technology, Liver Failure Treatment and Biotechnology Start-up.
Hexaell Biotech has completed 1 funding round, raising a total of $7.27M. The latest funding stage is Series A.
Top alternatives and competitors to Hexaell Biotech include Vital Therapies, 苏州吉美瑞生医学科技有限公司, Blue Cell Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hexaell Biotech and Vital Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Hexaell Biotech, https://bouncewatch.com/company/hexaell-biotech, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout